Insmed Incorporated
INSMNext catalyst
Arikayce™
Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen
Get an email about INSM's next catalysts
Track Insmed (INSM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline
2 upcoming, 1 past
Treprostinil Palmitil Phase 3 Est. Readout
Primary completion for Treprostinil Palmitil trial (NCT05649748) in Pulmonary Arterial Hypertension
SourceFDA PDUFA Date ARIKAYCE (priority)
For Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. sNDA filing. Extracted from SEC filing: EXHIBIT 99.1
SourceUpcoming FDA decisions
How INSM's past catalysts played out
Market Overview
Stock performance and key metrics
Liposomal amikacin for inhalation
Cystic Fibrosis
ALIS
Mycobacterium Infections, Nontuberculous
LAI (Liposomal Amikacin for Inhalation)
Mycobacterium Infections, Nontuberculous
rhIGF-I/rhIGFBP-3
Myotonic Dystrophy Type 1
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer
Pseudomonas Aeruginosa Infection
Ethambutol
Mycobacterium Infections, Nontuberculous
ELC
Mycobacterium Infections, Nontuberculous
Multi-drug regimen
NTM Lung Infection Due to MAC
LAI
NTM Lung Infection Due to MAC
Treprostinil Palmitil Inhalation Powder
Pulmonary Hypertension
Brensocatib
Hidradenitis Suppurativa
Treprostinil Palmitil
Pulmonary Hypertension
Cisplatin liposomal
Osteosarcoma Metastatic
Mometasone furoate nasal spray (MFNS)
Chronic Rhinosinusitis Without Nasal Polyps
OpSCF
Atopic Dermatitis
Arikayce™
Cystic Fibrosis
ARIKACE™
Cystic Fibrosis
Liposomal amikacin for inhalation (LAI)
Mycobacterium Infections, Nontuberculous
LAI plus multi-drug regimen
Mycobacterium Infections, Nontuberculous
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Liposomal amikacin for inhalation | Phase 3 | Cystic Fibrosis | - | - |
ALIS | Phase 3 | Mycobacterium Infections, Nontuberculous | - | - |
LAI (Liposomal Amikacin for Inhalation) | Phase 3 | Mycobacterium Infections, Nontuberculous | - | - |
rhIGF-I/rhIGFBP-3 | Phase 3 | Myotonic Dystrophy Type 1 | - | - |
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer | Phase 3 | Pseudomonas Aeruginosa Infection | - | - |
Ethambutol | Phase 3 | Mycobacterium Infections, Nontuberculous | - | - |
ELC | Phase 3 | Mycobacterium Infections, Nontuberculous | - | - |
Multi-drug regimen | Phase 3 | NTM Lung Infection Due to MAC | - | - |
LAI | Phase 3 | NTM Lung Infection Due to MAC | - | - |
Treprostinil Palmitil Inhalation Powder | Phase 3 | Pulmonary Hypertension | - | - |
Brensocatib | Phase 3 | Hidradenitis Suppurativa | - | - |
Treprostinil Palmitil | Phase 3 | Pulmonary Hypertension | - | - |
Cisplatin liposomal | Phase 2 | Osteosarcoma Metastatic | - | - |
Mometasone furoate nasal spray (MFNS) | Phase 2 | Chronic Rhinosinusitis Without Nasal Polyps | - | - |
OpSCF | Phase 2 | Atopic Dermatitis | - | - |
Arikayce™ | Phase 2 | Cystic Fibrosis | - | - |
ARIKACE™ | Phase 2 | Cystic Fibrosis | - | - |
Liposomal amikacin for inhalation (LAI) | Phase 2 | Mycobacterium Infections, Nontuberculous | - | - |
LAI plus multi-drug regimen | Phase 2 | Mycobacterium Infections, Nontuberculous | - | - |
Cystic Fibrosis
5 drugs in this indication
Mycobacterium Infections, Nontuberculous
4 drugs in this indication
NTM Lung Infection Due to MAC
2 drugs in this indication
Non-Cystic Fibrosis Bronchiectasis
2 drugs in this indication
Pulmonary Hypertension
2 drugs in this indication
Hidradenitis Suppurativa
1 drug in this indication
Myotonic Dystrophy Type 1
1 drug in this indication
Osteosarcoma Metastatic
1 drug in this indication
Pseudomonas Aeruginosa Infection
1 drug in this indication
Bronchiectasis
1 drug in this indication
Chronic Rhinosinusitis Without Nasal Polyps
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Insmed Incorporated's drug pipeline?→
CatalystAlert tracks 19 drug candidates in Insmed Incorporated's (INSM) pipeline across Phase 3, Phase 2. Its lead program is Arikayce™ (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Insmed Incorporated's next FDA catalyst?→
Insmed Incorporated's (INSM) next tracked catalyst is a PDUFA date expected Jan 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INSM biotech catalysts?→
Add INSM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Insmed Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
